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background: Double opposed helical (DH) biodegradable stents (BDS) enable manufacturing to diameters applicable to congenital heart disease. 
The primary objective is to evaluate delivery and deployment of 6 and 8mm diameter DH BDS in a porcine animal model. Secondary objectives are 
to evaluate patency, thrombosis, and inflammation at 1-week, 1 and 9-months.
methods: 6 and 8mm diameter DH BDS were manufactured with poly-L-lactic acid fiber and delivered in the external iliac artery (EIA) and distal 
descending aorta (DAO) of Sinclair minipigs. Patency and thrombosis was assessed at 1-week, 1 and 9-months with angiography and intravascular 
ultrasound. Histopathology was performed at each time interval.
results: 14 stents were placed in 9 animals: 8mm (8) and 6mm (1) were delivered in the DAO and 6mm (5) in the EIA. The 8mm diameter stent 
required a 9Fr delivery sheath. 8mm stents were frequently too small for this model with embolization of 4/9 stents requiring recapturing and 
redilation. All stents remained patent with no thrombosis. There was mild neointimal proliferation (NIP) at 1 week and 1 month and moderate NIP at 
9-months follow-up. Neoendothelialization was complete at 1 month.
conclusions: DH BDS designed to 8mm diameter have been manufactured and implanted. A sustained, significant inflammatory response with 
moderate NIP was seen at 9 months. Further improvements in fiber properties, investigation of anti-inflammatory drug coatings and miniaturization 
for ease of delivery are needed.
